ArticleFrontiers in immunology2025
The predictive value of Naples prognostic score for patients with locally advanced non-small cell lung cancer undergoing surgery after neoadjuvant chemotherapy.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Comparative Prognostic Performance of CARWL and Naples Prognostic Score in Stage IIIC Non-Small Cell Lung Cancer Treated with Definitive Chemoradiotherapy.Medical sciences (Basel, Switzerland) · 2026Article
- The predictive value of modified-Naples prognostic score for patients with locally advanced non-small cell lung cancer undergoing surgery after neoadjuvant chemotherapy.Frontiers in immunology · 2026Article
- Development of a Prognostic Nomogram Model and Establishment of a Risk Stratification System Based on the Naples Prognostic Score for Patients with Oropharyngeal Squamous Cell Carcinoma Who Have Undergone Radical Surgery.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the prognostic significance of the Naples Prognostic Score (NPS) in patients with locally advanced non-small cell lung cancer (NSCLC) after neoadjuvant chemotherapy and surgery. Methods: A retrospective review was done of 126 patients with locally advanced NSCLC who were surgically treated Affiliated Hospital of Weifang Medical University. from September 2012 to April 2019. According to the neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), albumin, and total cholesterol before neoadjuvant chemotherapy, NPS was divided into separate groups: group 0, group 1, and group 2. Kaplan-Meier method was used to analyze survival curves for the NPS. Univariate and multivariate Cox analysis of overall survival (OS) and progression-free survival (PFS) was then conducted. Results: This study included 60 male and 66 female patients, with the median age being 59 (59.94 ± 11.77). Based on the NPS system, the three groups were divided: Group 0, 41(32.5%) patients; Group 1, 55(43.7%) patients; and Group 2, 30(23.8%) patients. Smoking status (P=0.032) and KPS score (P=0.018) were significantly different among the three NPS groups, but it had no statistical relevance in regards to gender (P=0.849), age (P=0.474), clinical stage (P=0.101), pathology (P=0.819), tumor location (P=0.304), degree of differentiation (P=0.889), surgical method (P=0.436), chemotherapy (P=0.718), postoperative complications (P=0.177) or CEA level (P=0.447). Univariate Analysis showed that clinical stage (P=0.004), KPS score (P=0.003), surgery approach (P=0.042) and NPS (Group 2 vs. Group 0, P< 0.001; Group 1 vs. Group 0, P=0.005) were predictors of OS in patients with locally advanced NSCLC, and that clinical stage (P=0.005), KPS score (P=0.002), and NPS (Group 2 vs. Group 0, P< 0.001; Group 1 vs. group 0, P=0.001) were significantly associated with PFS. Based on the positive results of univariate analysis, we performed multivariate analysis. Multivariate Cox Regression showed that the NPS was a significant independent predictor of worse OS (Group 2 vs. Group 0, P=0.006; Group 1 vs. group 0, P=0.017) and PFS (group 2 vs. group 0, P=0.006; Group 1 vs group 0, P=0.011). Conclusion: As a clinically accessible blood indicator, NPS has vital value in predicting the prognosis of resected locally advanced NSCLC patients receiving neoadjuvant chemotherapy and surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.